MorphoSys AG (MOR): Price and Financial Metrics
GET POWR RATINGS... FREE!
MOR Stock Price Chart Interactive Chart >
MOR Price/Volume Stats
| Current price | $3.96 | 52-week high | $7.45 |
| Prev. close | $4.12 | 52-week low | $3.17 |
| Day low | $3.90 | Volume | 439,400 |
| Day high | $3.99 | Avg. volume | 144,865 |
| 50-day MA | $4.46 | Dividend yield | N/A |
| 200-day MA | $4.70 | Market Cap | 542.23M |
MorphoSys AG (MOR) Company Bio
MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.
Latest MOR News From Around the Web
Below are the latest news stories about MORPHOSYS AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.
MorphoSys AG (NASDAQ:MOR) Q4 2022 Earnings Call TranscriptMorphoSys AG (NASDAQ:MOR) Q4 2022 Earnings Call Transcript March 16, 2023 Julia Neugebauer: Ladies and gentlemen, good afternoon and good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys, and it’s my pleasure to welcome you to our Fourth Quarter and Full Year 2022 Financial Results Conference Call. Joining me on the […] |
MorphoSys Full Year 2022 Earnings: Beats ExpectationsMorphoSys ( ETR:MOR ) Full Year 2022 Results Key Financial Results Revenue: €278.3m (up 55% from FY 2021). Net loss... |
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdatePLANEGG/MUNICH, Germany, March 15, 2023--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022. |
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). |
MorphoSys Stops Work and Operations on Pre-Clinical Research ProgramsMorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs are promising, MorphoSys would need to make substantial investments to bring these programs into the clinic. As a result, MorphoSys will reduce its workforce at the company's headquarters in Planegg, Germany, by approximately 17%. |
MOR Price Returns
| 1-mo | -8.33% |
| 3-mo | 10.61% |
| 6-mo | -23.99% |
| 1-year | -43.43% |
| 3-year | -83.81% |
| 5-year | N/A |
| YTD | 10.61% |
| 2022 | -62.00% |
| 2021 | -66.76% |
| 2020 | -20.55% |
| 2019 | 40.99% |
| 2018 | N/A |
Continue Researching MOR
Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...